In a report published Tuesday, Deutsche Bank analyst Gregg Gilbert initiated coverage on Ligand Pharmaceuticals LGND with a Buy rating and $74.00 price target.
In the report, Deutsche Bank noted, “We are initiating coverage of Ligand with a Buy rating and $74 target price. We view Ligand as an increasingly attractive cash flow story based on strong revenue growth coupled with significant operating leverage and a low tax rate. The company's diverse revenue base and extensive pipeline of owned and partnered products create a relatively unique investment opportunity within pharma/biotech, in our view. While business development remains a strategic priority, we expect the company to consider other routes of shareholder return as cash continues to accumulate. With ~$190mn of cash on hand post the recent convert offering, we would be disappointed if management did not deploy a significant portion in the next 6-12 months.”
Ligand Pharmaceuticals closed on Monday at $52.57.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in